BRAF and melanoma: Patients with unresectable stage IIIc–IV, BRAF V600E mutant melanoma were randomly assigned 1:1 to 28-day cycles of vemurafenib (960 mg b.i.d.), and cobimetinib (60 mg/d for 21 days) with either atezolizumab (840 mg) or placebo.